Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1269 • ACR Convergence 2023
The Impact of Sex, Serostatus, and Smoking on Risk for Rheumatoid Arthritis-associated Interstitial Lung Disease Subtypes
Gregory McDermott¹, Keigo Hayashi¹, Pierre-Antoine Juge², Ritu Gill¹, Suzanne Byrne¹, Staci Gagne¹, Kathleen Vanni¹, Emily Kowalski¹, Grace Qian¹, Katarina Bade³, Alene Saavedra¹, Yumeko Kawano¹, Michael Diiorio³, Taylor Wolfgang¹, Edy Kim¹, Paul Dellaripa³, Michael Weinblatt⁴, Nancy Shadick³, Tracy J. Doyle¹ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Harvard Medical School, Waban, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is a heterogenous condition encompassing multiple subtypes with varying histopathology, prognosis, and potential treatment options. The most common RA-ILD…
Abstract Number: 1285 • ACR Convergence 2023
PROMIS Symptom Clusters Predict Disease Activity in the First 6 Months in Newly Diagnosed RA Patients Starting MTX Therapy: Data from the Canadian Early Arthritis Cohort
Susan Bartlett¹, Clifton Bingham², Orit Schieir³, Marie-France Valois⁴, Gilles Boire⁵, Louis Bessette⁶, Janet Pope⁷, Diane Tin⁸, Carter Thorne⁹, Glen Hazlewood¹⁰, Carol Hitchon¹¹, Edward Keystone¹² and Vivian Bykerk¹³, ¹McGill University, Montreal, QC, Canada, ²Johns Hopkins Medicine, Baltimore, MD, ³McGill University, Montréal, QC, Canada, ⁴McGill University, Pointe-Claire, QC, Canada, ⁵Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, ⁷University of Western Ontario, London, ON, Canada, ⁸Newmarket Rheumatology Consultants, Newmarket, ON, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹University of Manitoba, Winnipeg, MB, Canada, ¹²Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹³Hospital for Special Surgery, New York, NY
Background/Purpose: We have previously shown that PROMIS-29 physical (pain, fatigue) and emotional (depression, anxiety) symptom clusters can be used to identify 4 distinct early RA…
Abstract Number: 1301 • ACR Convergence 2023
The Relationship Between Socioeconomic Factors and Persistent Active Rheumatoid Arthritis: Results from (NEIAA) a Large UK Cohort of Early Inflammatory Arthritis
Maryam Adas¹, Sam Norton¹, Andrew Cope¹, Maya Buch², James Galloway¹ and Elena Nikiphorou¹, ¹King's College London, London, United Kingdom, ²University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: Psychosocial factors may interplay with biological factors to drive a refractory disease state in patients with inflammatory arthritis1. We aim to explore which socioeconomic,…
Abstract Number: 1317 • ACR Convergence 2023
Discontinuation of Biological Disease Modifying Drugs Due to Adverse Drug Reactions in an Inception Rheumatoid Arthritis Cohort
Zulema Rosales-Rosado¹, Maria Rodriguez Laguna², Cristina lajas Petisco², Clara De Miguel² and lydia Abasolo¹, ¹Hospital Clínico San Carlos, Madrid, Spain, ²Hospital Clinico San Carlos, Madrid, Spain
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatic patients due, mainly, to the use of Disease Modifying Drugs (DMARD).…
Abstract Number: 1334 • ACR Convergence 2023
Comparison of Malignancies and Serious Infections Between Etanercept Biosimilar and Bio-Originator Initiators: Population-Based Analyses
Marina Birck¹, Luck Lukusa², Michal Abrahamowicz³, Gilles Boire⁴, Denis Choquette⁵, Walter P. Maksymowych⁶ and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²RI-MUHC, Montreal, QC, Canada, ³McGill University, Verdun, QC, Canada, ⁴Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ⁶University of Alberta, Edmonton, AB, Canada
Background/Purpose: Treatment safety, particularly malignancy and infections, is an important issue for biologics; hence, surveillance and analyses comparing biosimilar versus bio-originator use in the real…
Abstract Number: 1363 • ACR Convergence 2023
Plasma Neutrophil Extracellular Trap Remnant Levels Are Lower in Premenopausal Healthy Women Using Oral Contraceptive Pills
Background/Purpose: Women develop RA 3 times more often than men, and several risk factors for RA are female specific. Prior studies demonstrate an association between…
Abstract Number: 1680 • ACR Convergence 2023
What Trade-offs Are Acceptable to Rheumatoid Arthritis Patients During Treatment Selection?
Rieke Alten¹, Juan carlos Nieto-Gonzalez², Peggy Jacques³, Carlomaurizio Montecucco⁴, Robert Moots⁵, Helga Radner⁶, Sebastian Heidenreich⁷, Chiara Whichello⁷, Nicolas Krucien⁷, Monia Zignani⁸, Harald Vonkeman⁹ and Katrien Van Beneden¹⁰, ¹Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, ²Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Department of Rheumatology and VIB Inflammation Research Center, University Hospital Ghent, Ghent, Belgium, ⁴Division of Rheumatology, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ⁵Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom, ⁶Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁷Patient-centred Research, Evidera Inc., London, United Kingdom, ⁸Medical Affairs, Galapagos GmbH, Basel, Switzerland, ⁹Department of Rheumatology, Medisch Spectrum Twente and University of Twente, Enschede, Netherlands, ¹⁰Medical Safety, Galapagos NV, Mechelen, Belgium
Background/Purpose: Multiple RA therapies are available that differ in attributes such as mode of administration and benefit-risk profile. Challenging trade-offs are made during treatment selection…
Abstract Number: 1735 • ACR Convergence 2023
An Unorthodox HLA-DRhiCD15+ ‘Hybrid’ Population in Rheumatoid Arthritis Characterized Using Spectral Cytometry
Christian Geier¹, Haani Qudsi², Jihad BenGabr¹, Robert Winchester³ and Andras Perl⁴, ¹SUNY Upstate Medical University, Syracuse, NY, ²Norton College of Medicine, SUNY Upstate Medical University, Syracuse, NY, ³Columbia University, New York, NY, ⁴SUNY, Syracuse, NY
Background/Purpose: A variant of HLA-DR confers the strongest genetic risk for rheumatoid arthritis (RA) suggesting that DRhi cells are important in RA. We previously found…
Abstract Number: 1751 • ACR Convergence 2023
Profiling of Anti-PAD IgG and IgA in Patients from the Head-to-head Adalimumab vs Abatacept Rheumatoid Arthritis AMPLE Trial and Matched Healthy Controls
Namit Kumar¹, Xueer Chen², Mary Ann Aure³, Andy Ishii⁴, Laura Martinez-Prat⁵, chelsea Bentow⁴, Jasmine Saini², Michael Mahler⁴ and Laurence Menard², ¹Bristol Myers Squibb, San Diego, CA, ²Bristol Myers Squibb, Princeton, NJ, ³Werfen, Chula Vista, CA, ⁴Werfen, San Diego, CA, ⁵Werfen Autoimmunity, Sant Cugat del Vallès, Spain
Background/Purpose: A hallmark of rheumatoid arthritis (RA) is the presence of anti-citrullinated protein antibodies (ACPA) targeting neoantigens which are generated by a family of enzymes…
Abstract Number: 1767 • ACR Convergence 2023
TNF-α Utilizes the TWEAK/Fn-14 Axis in Human Rheumatoid Arthritis Synovial Fibroblasts to Induce Inflammation
Farheen Sultan Shaikh¹, Anil Singh¹, Paul Panipinto² and Salahuddin Ahmed¹, ¹Washington State University, Spokane, WA, ²Washington State University College of Pharmaceutical Science and Molecular Medicine, Spokane, WA
Background/Purpose: Tumor necrosis factor-alpha (TNF)-α is a proinflammatory cytokine in rheumatoid arthritis that transduces intracellular signal transduction pathways through specific receptors, TNF-R1, and TNF-R2. The…
Abstract Number: 1860 • ACR Convergence 2023
Evaluation of the Receipt of Adequate Pharmacological and Psychological Treatment for Incident Depression and Anxiety in Individuals Living with Inflammatory Arthritis
Alyssa Howren¹, Eric Sayre², J. Antonio Avina-Zubieta³, Joseph Puyat¹, Deborah Da Costa⁴, Hui Xie⁵, Amit Gupta¹ and Mary De Vera¹, ¹University of British Columbia, Vancouver, BC, Canada, ²British Columbia Centre on Substance Use, Vancouver, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴McGill University, Pointe-Claire, QC, Canada, ⁵Simon Fraser University, Richmond, BC, Canada
Background/Purpose: To describe patterns of pharmacological and psychological treatment and evaluate the receipt of minimally adequate treatment for incident depression and anxiety in individuals with…
Abstract Number: 1934 • ACR Convergence 2023
Pooled Safety Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis
Stanley Cohen¹, Shaun Bender², Amy Shaberman³, Richard Vinisko³ and Dorothy McCabe³, ¹University of Texas Southwestern, Dallas, TX, ²Alnylam Pharmaceuticals, Cambridge, MA, ³Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT
Background/Purpose: The VOLTAIRE trials program compared the safety, efficacy, and immunogenicity of biosimilar BI 695501 with adalimumab reference product (RP) for indications including moderate-severe rheumatoid…
Abstract Number: 2105 • ACR Convergence 2023
Cohort-wide Immuno-phenotype Deconvolute Immunological and Clinical Heterogeneity Across Autoimmune Rheumatic Diseases
Hiroaki Tanaka¹, Yukinori Okada², Shingo Nakayamada¹, Yusuke Miyazaki³, Kyuto Sonehara⁴, Shinichi Namba⁵, Suguru Honda⁶, Yuya Shirai⁷, Kenichi Yamamoto⁵, Katsunori Ikari⁸, Masayoshi Harigai⁹, KOSHIRO SONOMOTO¹⁰ and Yoshiya Tanaka¹, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²University of Tokyo / Osaka University / RIKEN, Tokyo, Japan, ³The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kiakyusyu Fukuoka, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵Osaka University, Osaka, Japan, ⁶Tokyo Women's Medical University, Tokyo, Japan, ⁷Osaka University, Suita, Japan, ⁸Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ⁹Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ¹⁰University of Occupational and Environmental Health, Beppu, Japan
Background/Purpose: Autoimmune rheumatic diseases (AIRDs) are systemic but heterogeneous diseases characterized by orchestration of disrupted self-tolerance of immune systems. We face a challenge in characterizing…
Abstract Number: 2121 • ACR Convergence 2023
Clinical Significance of Negative Seroconversion of Anti-CCP and Anti-Mutated Citrullinated Vimentin Antibodies in Patients with Rheumatoid Arthritis
Takao Fujii, Katsunori Tanaka, Ryo Matsumiya, Kayoko Tabata and Shigeru Iwata, Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan
Background/Purpose: Anti-cyclic citrullinated peptide antibody (anti-CCP Ab) positivity is closely associated with bone destruction in rheumatoid arthritis (RA) patients, but the correlation between the Ab…
Abstract Number: 2137 • ACR Convergence 2023
Line of Therapy of Biologics and JAK Inhibitors in RA, PsA and AxSpA: Implications for Design and Uptake of New Drugs and Diagnostics
Jeffrey Curtis¹, Fenglong Xie¹, Yuji Su², Patrick Stewart³ and Amy S. Mudano¹, ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham and Illumination Health, Birmingham, AL, ³Illumination Health, Birmingham, AL
Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA) have an increasing array of treatment options available, and new blood-based diagnostic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].